Top Quality Carbidopa Levodopa/ Carbidopa Powder CAS 38821-49-7

• Powder: Yes
• Customized: Non-Customized
• Certification: USP
• Suitable for: Elderly
• State: Solid
• Purity: >98%
• Model NO.: 201906030344
• Name: Carbidopa
• Other Names: Carbidopa Powder
• Other Name: Carbidopa Capsules
• Fuction: Health Care
• Original: API
• Specifications: 99%
• CAS: 38821-49-7
• Color: White
• Form: Powder
• Grade: Pharma
• MOQ: 10g
• Storage: Cool Dry Place
• Shelf Life: 2 Years
• Brand Name: Tgy
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: TGYBIO
• Origin: China
• HS Code: 2019051403
• Production Capacity: 50kg/Month

Product Description

Carbidopa and Levodopa extended release tablets are extended release combination of Carbidopa and Levodopa for the treatment of Parkinson's disease and syndrome.

Items		Specification	Results
Character	Appearance	White to creamy white powder	Creamy white powder
	Solubility	Slightly soluble in water,  practically insoluble in alcohol,ether.	Meets the requirements
Identification	A,IR	The spectrum of sample complies with the spectrum obtained with standard	Complies
	RT	Corresponds to the peak obtained with the standard	Corresponds
Specific rotation		-21.0°~ -23.5°	-21.8°
Loss on drying		6.9% ~ 7.9%	7.2%
Residue on ignition		≤0.1%	0.02%
Heavy metals		≤0.001%	<0.001%
Methyldopa		≤0.5%	0.30%
Carbidopa related compound A		≤0.5%	Undetected
Any other impurity		≤0.10%	0.06%
Total impurities		≤1.0%	0.44%
Residual solvents		Meets the requirements.	Meets the requirements.
Assay		98.0~102.0%	99.8%

Carbidopa with strong outer peripheral dopa decarboxylase inhibitors. Easy through the blood-brain barrier, in combination with levodopa, suppress only the outer peripheral dopa decarboxylase activity, reducing the generation of dopamine in peripheral tissues, reduce adverse reactions outer periphery, thereby enabling an increase in levodopa into the hub, improve brain dopamine concentration, enhance the efficacy of levodopa, it is an important adjunct to levodopa.